Genetic control of the alternative pathway of complement in humans and age-related macular degeneration

Laura A. Hecker, Albert O. Edwards, Euijung Ryu, Nirubol Tosakulwong, Keith Baratz, William L. Brown, Peter Charbel Issa, Hendrik P. Scholl, Beatrix Pollok-Kopp, Katharina E. Schmid-Kubista, Kent R Bailey, Martin Oppermann

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

Activation of the alternative pathway of complement is implicated in common neurodegenerative diseases including age-related macular degeneration (AMD). We explored the impact of common variation in genes encoding proteins of the alternative pathway on complement activation in human blood and in AMD. Genetic variation across the genes encoding complement factor H (CFH), factor B (CFB) and component 3 (C3) was determined. The influence of common haplotypes defining transcriptional and translational units on complement activation in blood was determined in a quantitative genomic association study. Individual haplotypes in CFH and CFB were associated with distinct and novel effects on plasma levels of precursors, regulators and activation products of the alternative pathway of complement in human blood. Further, genetic variation in CFH thought to influence cell surface regulation of complement did not alter plasma complement levels in human blood. Plasma markers of chronic activation (split-products Ba and C3d) and an activating enzyme (factor D) were elevated in AMD subjects. Most of the elevation in AMD was accounted for by the genetic variation controlling complement activation in human blood. Activation of the alternative pathway of complement in blood is under genetic control and increases with age. The genetic variation associated with increased activation of complement in human blood also increased the risk of AMD. Our data are consistent with a disease model in which genetic variation in the complement system increases the risk of AMD by a combination of systemic complement activation and abnormal regulation of complement activation in local tissues.

Original languageEnglish (US)
Article numberddp472
Pages (from-to)209-215
Number of pages7
JournalHuman Molecular Genetics
Volume19
Issue number1
DOIs
StatePublished - Oct 13 2009

Fingerprint

Alternative Complement Pathway
Macular Degeneration
Complement Activation
Complement Factor H
Haplotypes
Neurodegenerative Diseases
Enzymes

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Molecular Biology

Cite this

Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. / Hecker, Laura A.; Edwards, Albert O.; Ryu, Euijung; Tosakulwong, Nirubol; Baratz, Keith; Brown, William L.; Issa, Peter Charbel; Scholl, Hendrik P.; Pollok-Kopp, Beatrix; Schmid-Kubista, Katharina E.; Bailey, Kent R; Oppermann, Martin.

In: Human Molecular Genetics, Vol. 19, No. 1, ddp472, 13.10.2009, p. 209-215.

Research output: Contribution to journalArticle

Hecker, LA, Edwards, AO, Ryu, E, Tosakulwong, N, Baratz, K, Brown, WL, Issa, PC, Scholl, HP, Pollok-Kopp, B, Schmid-Kubista, KE, Bailey, KR & Oppermann, M 2009, 'Genetic control of the alternative pathway of complement in humans and age-related macular degeneration', Human Molecular Genetics, vol. 19, no. 1, ddp472, pp. 209-215. https://doi.org/10.1093/hmg/ddp472
Hecker, Laura A. ; Edwards, Albert O. ; Ryu, Euijung ; Tosakulwong, Nirubol ; Baratz, Keith ; Brown, William L. ; Issa, Peter Charbel ; Scholl, Hendrik P. ; Pollok-Kopp, Beatrix ; Schmid-Kubista, Katharina E. ; Bailey, Kent R ; Oppermann, Martin. / Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. In: Human Molecular Genetics. 2009 ; Vol. 19, No. 1. pp. 209-215.
@article{0a9d77fbb15c4f3a94bd01a8cc291232,
title = "Genetic control of the alternative pathway of complement in humans and age-related macular degeneration",
abstract = "Activation of the alternative pathway of complement is implicated in common neurodegenerative diseases including age-related macular degeneration (AMD). We explored the impact of common variation in genes encoding proteins of the alternative pathway on complement activation in human blood and in AMD. Genetic variation across the genes encoding complement factor H (CFH), factor B (CFB) and component 3 (C3) was determined. The influence of common haplotypes defining transcriptional and translational units on complement activation in blood was determined in a quantitative genomic association study. Individual haplotypes in CFH and CFB were associated with distinct and novel effects on plasma levels of precursors, regulators and activation products of the alternative pathway of complement in human blood. Further, genetic variation in CFH thought to influence cell surface regulation of complement did not alter plasma complement levels in human blood. Plasma markers of chronic activation (split-products Ba and C3d) and an activating enzyme (factor D) were elevated in AMD subjects. Most of the elevation in AMD was accounted for by the genetic variation controlling complement activation in human blood. Activation of the alternative pathway of complement in blood is under genetic control and increases with age. The genetic variation associated with increased activation of complement in human blood also increased the risk of AMD. Our data are consistent with a disease model in which genetic variation in the complement system increases the risk of AMD by a combination of systemic complement activation and abnormal regulation of complement activation in local tissues.",
author = "Hecker, {Laura A.} and Edwards, {Albert O.} and Euijung Ryu and Nirubol Tosakulwong and Keith Baratz and Brown, {William L.} and Issa, {Peter Charbel} and Scholl, {Hendrik P.} and Beatrix Pollok-Kopp and Schmid-Kubista, {Katharina E.} and Bailey, {Kent R} and Martin Oppermann",
year = "2009",
month = "10",
day = "13",
doi = "10.1093/hmg/ddp472",
language = "English (US)",
volume = "19",
pages = "209--215",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Genetic control of the alternative pathway of complement in humans and age-related macular degeneration

AU - Hecker, Laura A.

AU - Edwards, Albert O.

AU - Ryu, Euijung

AU - Tosakulwong, Nirubol

AU - Baratz, Keith

AU - Brown, William L.

AU - Issa, Peter Charbel

AU - Scholl, Hendrik P.

AU - Pollok-Kopp, Beatrix

AU - Schmid-Kubista, Katharina E.

AU - Bailey, Kent R

AU - Oppermann, Martin

PY - 2009/10/13

Y1 - 2009/10/13

N2 - Activation of the alternative pathway of complement is implicated in common neurodegenerative diseases including age-related macular degeneration (AMD). We explored the impact of common variation in genes encoding proteins of the alternative pathway on complement activation in human blood and in AMD. Genetic variation across the genes encoding complement factor H (CFH), factor B (CFB) and component 3 (C3) was determined. The influence of common haplotypes defining transcriptional and translational units on complement activation in blood was determined in a quantitative genomic association study. Individual haplotypes in CFH and CFB were associated with distinct and novel effects on plasma levels of precursors, regulators and activation products of the alternative pathway of complement in human blood. Further, genetic variation in CFH thought to influence cell surface regulation of complement did not alter plasma complement levels in human blood. Plasma markers of chronic activation (split-products Ba and C3d) and an activating enzyme (factor D) were elevated in AMD subjects. Most of the elevation in AMD was accounted for by the genetic variation controlling complement activation in human blood. Activation of the alternative pathway of complement in blood is under genetic control and increases with age. The genetic variation associated with increased activation of complement in human blood also increased the risk of AMD. Our data are consistent with a disease model in which genetic variation in the complement system increases the risk of AMD by a combination of systemic complement activation and abnormal regulation of complement activation in local tissues.

AB - Activation of the alternative pathway of complement is implicated in common neurodegenerative diseases including age-related macular degeneration (AMD). We explored the impact of common variation in genes encoding proteins of the alternative pathway on complement activation in human blood and in AMD. Genetic variation across the genes encoding complement factor H (CFH), factor B (CFB) and component 3 (C3) was determined. The influence of common haplotypes defining transcriptional and translational units on complement activation in blood was determined in a quantitative genomic association study. Individual haplotypes in CFH and CFB were associated with distinct and novel effects on plasma levels of precursors, regulators and activation products of the alternative pathway of complement in human blood. Further, genetic variation in CFH thought to influence cell surface regulation of complement did not alter plasma complement levels in human blood. Plasma markers of chronic activation (split-products Ba and C3d) and an activating enzyme (factor D) were elevated in AMD subjects. Most of the elevation in AMD was accounted for by the genetic variation controlling complement activation in human blood. Activation of the alternative pathway of complement in blood is under genetic control and increases with age. The genetic variation associated with increased activation of complement in human blood also increased the risk of AMD. Our data are consistent with a disease model in which genetic variation in the complement system increases the risk of AMD by a combination of systemic complement activation and abnormal regulation of complement activation in local tissues.

UR - http://www.scopus.com/inward/record.url?scp=77649291314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649291314&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddp472

DO - 10.1093/hmg/ddp472

M3 - Article

VL - 19

SP - 209

EP - 215

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 1

M1 - ddp472

ER -